(Q36430311)

14 August 2017

1 reference

title

Applications of genomics in NSCLC. (English)

1 reference

14 August 2017

0 references

1

Rafael Rosell

1 reference

14 August 2017

Manuel Cobo

2

1 reference

14 August 2017

Dolores Isla

3

1 reference

14 August 2017

Jose Miguel Sanchez

4

1 reference

14 August 2017

Miquel Taron

5

1 reference

14 August 2017

Giuseppe Altavilla

6

1 reference

14 August 2017

Mariacarmela Santarpia

7

1 reference

14 August 2017

Teresa Moran

8

1 reference

14 August 2017

Silvia Catot

9

1 reference

14 August 2017

Olatz Etxaniz

10

1 reference

14 August 2017

publication date

1 December 2005

1 reference

14 August 2017

1 reference

14 August 2017

volume

50 Suppl 2

1 reference

14 August 2017

page(s)

S33-40

1 reference

Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2805%2981571-5

7 January 2021

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2805%2981571-5

7 January 2021

Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2805%2981571-5

7 January 2021

Genetic testing for chemotherapy in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2805%2981571-5

7 January 2021

Targeted therapy in combination with gemcitabine in non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2805%2981571-5

7 January 2021

Influence of genetic markers on survival in non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2805%2981571-5

7 January 2021

Nucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2805%2981571-5

7 January 2021

Oncogenic H-Ras up-regulates expression of ERCC1 to protect cells from platinum-based anticancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2805%2981571-5

7 January 2021

Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2805%2981571-5

7 January 2021

Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2805%2981571-5

7 January 2021

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2805%2981571-5

7 January 2021

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2805%2981571-5

7 January 2021

Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2805%2981571-5

7 January 2021

Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2805%2981571-5

7 January 2021

Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2805%2981571-5

7 January 2021

Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2805%2981571-5

7 January 2021

DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2805%2981571-5

7 January 2021

An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2805%2981571-5

7 January 2021

Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2805%2981571-5

7 January 2021

Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2805%2981571-5

7 January 2021

ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2805%2981571-5

7 January 2021

ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2805%2981571-5

7 January 2021

Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2805%2981571-5

7 January 2021

Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2805%2981571-5

7 January 2021

BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2805%2981571-5

7 January 2021

Hallmarks of 'BRCAness' in sporadic cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2805%2981571-5

7 January 2021

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2805%2981571-5

7 January 2021

BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2805%2981571-5

7 January 2021

Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2805%2981571-5

7 January 2021

Multicenter, Randomized Trial for Stage IIIB or IV Non–Small-Cell Lung Cancer Using Weekly Paclitaxel and Carboplatin Followed by Maintenance Weekly Paclitaxel or Observation

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2805%2981571-5

7 January 2021

Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2805%2981571-5

7 January 2021

Consolidation Docetaxel After Concurrent Chemoradiotherapy in Stage IIIB Non–Small-Cell Lung Cancer: Phase II Southwest Oncology Group Study S9504

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2805%2981571-5

7 January 2021

Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human ovarian cancer cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2805%2981571-5

7 January 2021

Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2805%2981571-5

7 January 2021

Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2805%2981571-5

7 January 2021

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2805%2981571-5

7 January 2021

Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2805%2981571-5

7 January 2021

Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2805%2981571-5

7 January 2021

Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2805%2981571-5

7 January 2021

10.1016/S0169-5002(05)81571-5

Identifiers

DOI

1 reference

14 August 2017

1 reference